Opinion|Videos|May 23, 2024
Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
Author(s)Anjali Tiku Owens, MD
A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.
Advertisement
Episodes in this series
- What have we learned from clinical trials evaluating CMI’s for oHCM?
Hutt et al 2024
- Mavacamten: Outcomes; focused on feel and function
Olivotto et al 2020 ,Maron et al 2023 - Longer-term outcomes of the VALOR-HCM RCT
Desai et al 2023 - MAVA-LTE
- Aficamten: phase 2 REDWOOD-HCM soon to be completed, phase 3 trial SEQUIOA-HCM.
Masri et al 2022 ,Maron et al 2023
Advertisement
Related to this article
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes
3
Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care
4
New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity
5